COURAGE tested antibodies blocking GDF8 (trevogrumab) and activin A (garetosmab) for muscle loss during semaglutide-induced weight loss. The phase 2, double-blind, placebo-controlled trial randomised 975 adults with obesity at 60 US sites. Part A added placebo, trevogrumab 200 or 400 mg, or trevogrumab plus garetosmab to semaglutide for 26 weeks. Part B added placebo or trevogrumab 25 or 75 mg to semaglutide for 52 weeks. With semaglutide plus placebo, lean mass fell substantially by week 26. Endpoints were lean mass, fat mass and bodyweight, not muscle strength or function, and all sites were in the US.
Why it is interesting: Lean mass loss accompanies the rapid weight loss seen with GLP-1 receptor agonists. This large randomised trial tests whether blocking two negative regulators of muscle mass can offset that loss.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.